The book, *Targeted Therapy for lung cancer: Afatinib focused* is one of the most positively surprising enterprises realized by AME Publishing. It’s on the cutting edge of novel forms of lung cancer, especially treatable subclasses of lung adenocarcinoma, such as, EGFR mutant driven non-small-cell lung cancer (NSCLC). The work also encompasses multiple different subtypes of lung cancer, including salient aspects of squamous cell carcinoma of the lung, as well as the elusive, SCLC.

In cancer medicine, EGFR mutation driven NSCLC has become the paramount of success with targeted therapy. There have been continuous new discoveries and challenges regarding multiple forms of cancer resistance and both clinical investigators and laboratory researchers, alike, have never before seen cancer so up-close. Nevertheless, in spite of all the multi-tasked scientific endeavors, cancer cells are still capable of surviving and, ultimately, fulfill their function of consuming the patient.

The book is particularly useful since it has gathered together an impressive group of dedicated investigators, from bench to bed, who provide their expert opinion in several organized chapters.

The reader will be surprised from the first chapter to the last and will find all the elements of current knowledge easily absorbed with great satisfaction, thus encouraging them to join the knowledgeable investigators and coauthors in this ceaseless research towards the curability of lung cancer. The book has been structured in such a manner that the reader can choose to start reading in the order most suited to them. The book is mandatory for both medical oncologists in training and laboratory investigators, in order to get a closer glance at the lung cancer patient. The book amalgamates extraordinary authors from various geographic regions with different areas of skills and expertise and focuses on providing the most modern and satisfactory therapy in lung cancer, in all subclasses of lung cancer, especially EGFR mutation driven NSCLC.

In the last 60 years considerable progress has been made in cancer treatment and the book covers some astonishing advances accomplished within just the past decade. The fact that the book is guided by several experts in lung cancer permits us to travel through different and intriguing facets of the disease. Any advance is followed by a new failure or mechanism of resistance, prompting us to find a new solution.

In summary, it is without a doubt a great privilege and honor to be illuminated by such high regarded authors contributing with their deep experience and profound knowledge towards a momentous breakthrough in lung cancer therapy.

Rafael Rosell, MD
Director, Cancer Biology & Precision Medicine Program
Catalan Institute of Oncology
Germans Trias i Pujol Health Sciences Institute and Hospital
Badalona, Spain;
Oncology Institute Rosell
Quiron-Dexeus University Hospital
Barcelona, Spain
(Email: rrosell@iconcologia.net)